# hyperphagia associated with PWS FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hyperphagia-associated-with-pws

> No upcoming FDA catalysts in hyperphagia associated with PWS; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for hyperphagia associated with PWS?

No upcoming FDA catalysts in hyperphagia associated with PWS; 3 past events are recorded. Press release filed with the SEC (EX-99): "Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance in the second quarter of this year." [Calendar and source filings](https://sec-api.dev/indications/hyperphagia-associated-with-pws)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-082787, https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/ck0001774857-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-03-23. Cite: https://sec-api.dev/indications/hyperphagia-associated-with-pws#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 1H 2026 | [Hyperphagia topline data readout](https://sec-api.dev/pdufa/hyperphagia) | AARD | hyperphagia associated with PWS | scheduled | "We plan to initiate this trial in the second half of 2025 with anticipated topline data readout in the first half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1774857/000095017025047835/aard_10k_20241231.htm)) |
| early 2026 | [ARD-101 topline data readout](https://sec-api.dev/pdufa/ard-101) | AARD | hyperphagia associated with PWS | scheduled | "Ongoing ARD-101 Phase 3 HERO trial to treat hyperphagia associated with PWS is expected to generate topline data in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000095017025047769/ck0001774857-ex99_1.htm)) |
| Q3 2026 | [ARD-101 topline data readout](https://sec-api.dev/pdufa/ard-101) | AARD | hyperphagia associated with PWS | scheduled | "Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance in the second quarter of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/ck0001774857-ex99_1.htm)) |

## Drugs

- [Hyperphagia](https://sec-api.dev/pdufa/hyperphagia) (AARD)
- [ARD-101](https://sec-api.dev/pdufa/ard-101) (AARD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hyperphagia-associated-with-pws.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "hyperphagia associated with PWS FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hyperphagia-associated-with-pws

```bibtex
@misc{secapidev_indications_hyperphagia_associated_with_pws_20261116,
  title        = {hyperphagia associated with PWS FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hyperphagia-associated-with-pws}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hyperphagia_associated_with_pws_20261116","title":"hyperphagia associated with PWS FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hyperphagia-associated-with-pws","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
